253 related articles for article (PubMed ID: 10687988)
1. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
13. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A; Sternberg CN; Skoneczna I; Kovel S
BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Petrylak DP; Macarthur RB; O'Connor J; Shelton G; Judge T; Balog J; Pfaff C; Bagiella E; Heitjan D; Fine R; Zuech N; Sawczuk I; Benson M; Olsson CA
J Clin Oncol; 1999 Mar; 17(3):958-67. PubMed ID: 10071290
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
[TBL] [Abstract][Full Text] [Related]
19. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L
Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
